[Ip-health] Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity?"

joan rovira elrovira at yahoo.com
Fri May 10 08:24:22 PDT 2013



According to a 2011 study the first three biologicals
with biosimilar versions enjoyed a mean competition-free market position of no
less than 14.7 years in the 5 larger EU markets (Genotropin: 16.0; Neupogen, 15.2;
Eprex, 12.8)

Source: The impact of biosimilars’ entry in the EU
market. Joan Rovira,  Jaime Espín,
Leticia García and Antonio Olry de Labry, Andalusian School of Public Health, January,
2011 (p.29)
http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf


Table 5.  Duration
of the competition free market position of the reference products (years)
  Genotropin Neupogen Eprex All 
ITALY 18 16 15 16.3 
UK 19 18 17 18 
FRANCE 10 17 7 11.3 
GERMANY 18 7 6 10.3 
SPAIN 15 18 19 17.3 
MEAN 16 15.2 12.8 14.7 
Source:   Own elaboration based on IMS data 


________________________________
 








From: Ruth Lopert <ruth.lopert at gmail.com>
To: Jamie Love <james.love at keionline.org> 
Cc: ip-health <ip-health at lists.keionline.org>  
Sent: Friday, May 10, 2013 3:10 PM
Subject: Re: [Ip-health] Do Pharmaceutical Firms Invest More Heavily in Countries with Data Exclusivity?"
 

For the record biologics in the US have FOUR years of data exclusivity but
(and more egregiously ) TWELVE years of market exclusivity. If they had
twelve years of DE they'd effectively have 14 years of ME.

People really should stop using the terms interchangeably - there is a
world of difference


More information about the Ip-health mailing list